Structural and molecular interactions of CCR5 inhibitors with CCR5. - Wikidata - awgldk - TriplyDB

Structural and molecular interactions of CCR5 inhibitors with CCR5.

Structural and molecular interactions of CCR5 inhibitors with CCR5.

http://www.wikidata.org/entity/Q34494226

about

Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop Binding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonists Elucidating a key anti-HIV-1 and cancer-associated axis: the structure of CCL5 (Rantes) in complex with CCR5.P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions Solution Structure of LC4 Transmembrane Segment of CCR5 Identifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction network Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells Structural Analysis of Chemokine Receptor-Ligand Interactions.New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors Clinical use of CCR5 inhibitors in HIV and beyond HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5 Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.Analysis of Chemokine Receptor Trafficking by Site-Specific Biotinylation CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity.Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations HIV-1 drug resistance mutations: an updated framework for the second decade of HAART Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5.Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors.Pharmacological modulation of chemokine receptor function.Specific microbicides in the prevention of HIV infection.

P2860

Q21559473-4EE3DB98-E1E1-48E9-BC62-1DE040046D83 Q24658283-51AF677C-E419-4C09-93FE-11AC062DDC7C Q27309182-D833D1F0-137F-45EB-B779-B2453728A646 Q27321418-52CF9282-12E4-45F7-B61D-D6D56650D721 Q27666261-63681968-FA0B-429D-B112-8BA266B255C6 Q28533728-6B511B26-E795-4ACF-9836-8EB7E98794CA Q30366048-95A91C46-4E1A-4281-9BE6-7D603BEB5A76 Q30486707-0C21224F-19B1-4D15-B9B1-E6F40A5D4E9E Q33807529-B3481C21-1858-4F09-A927-E6C2FA16FB02 Q33890786-9633596E-FEFC-4879-A956-7346DA1C1A59 Q33961704-A897C776-C2CA-49C4-8C66-A5A11FF41868 Q33990552-61D70372-F05B-424E-8D3D-129BDB20E21A Q34550666-1B1BCD14-E88F-44AE-BD91-413950091F56 Q34568280-801809D2-37C4-435D-93D4-0D2A08589099 Q34606129-A652BE74-109A-4A3A-9ECC-7076894944FA Q34610959-EAF06856-5C76-469D-BA86-9BBE96D17B0F Q34641781-74D7A784-B903-4D47-BB27-A0C94AD92B9B Q35018145-37F6C78C-9B9D-472C-A42E-3659C80CC9FC Q35076868-AA497D40-EE98-4D00-995B-2960196F4013 Q35168976-C7DA3A67-C060-4853-B0FC-DFFDB56525B6 Q35312348-BD8F8BAE-4672-450B-AA58-962CACD28523 Q35665842-8DD5A72D-0665-4378-876B-8393AEEF6822 Q35911313-D9DD1FBB-CFE7-4502-907F-4F72C3969F4C Q35922555-2A5B4EF9-EF7F-4866-A03E-EA0A2DED8C8F Q36054360-54E9F190-FBA6-43C7-99D1-8BD790CB4651 Q36246273-0B5861D0-5FF3-4630-A8B1-8F3F7B3E98A3 Q36419287-73C0E046-ED77-4EEA-B72D-A498D9D793A4 Q36703042-0825F5AC-6A3D-47F2-84FF-68BF39333902 Q36827946-F682C3B8-8345-484B-BA51-E0A5971CC6DE Q36900010-0954B8FB-47E0-4EA1-8000-8EEDF0781B7D Q37071732-2FC7950F-4297-47F2-AAC5-6DD82977FC7C Q37360436-C96269E2-9E35-4CE6-B15E-07DD7F3396FB Q37421895-A90BF7D4-8C81-48BF-9312-2CF73D56E635 Q37452124-D0C7EA13-4DA3-4180-9E9B-C97D40C24B39 Q37463869-4154C786-776D-4CF0-B109-3D5469A34FD8 Q37502946-D8C874BB-FF05-4BAF-B80A-D599751E759D Q37780220-531632E6-DF05-46D4-985E-1C83E71906E9 Q37855900-181F4576-2672-47BF-B1FD-5437BEDCC220 Q37893687-1A0C69A5-6FA7-465D-AF58-47D4DEE46B23 Q37932048-7407849D-4BB8-413D-BCCF-9090430F4E09

P2860

Structural and molecular interactions of CCR5 inhibitors with CCR5.

http://www.wikidata.org/entity/Q34494226

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Structural and molecular interactions of CCR5 inhibitors with CCR5.

@ast

Structural and molecular interactions of CCR5 inhibitors with CCR5.

@en

Structural and molecular interactions of CCR5 inhibitors with CCR5.

@nl

type

label

Structural and molecular interactions of CCR5 inhibitors with CCR5.

@ast

Structural and molecular interactions of CCR5 inhibitors with CCR5.

@en

Structural and molecular interactions of CCR5 inhibitors with CCR5.

@nl

prefLabel

Structural and molecular interactions of CCR5 inhibitors with CCR5.

@ast

Structural and molecular interactions of CCR5 inhibitors with CCR5.

@en

Structural and molecular interactions of CCR5 inhibitors with CCR5.

@nl

P1433

Q34494226-E81569A5-0D2A-455C-9C71-1AF1264FFC32

P1476

Q34494226-878AEC64-CC98-43A3-BBB5-5350744356EA

P2093

Q34494226-050B8E34-4CD2-4E06-A0C3-203062F29F15

Q34494226-071AD25A-7DCA-42B1-8244-24FF21073993

Q34494226-099620C4-F66B-4BCB-ADC2-5EB2B93813DC

Q34494226-10A116EF-0144-4BA0-9349-EB3983F5A80E

Q34494226-18957F70-4C11-4EA5-9602-B3FE8F12AC3D

Q34494226-1BB8D92F-AAD4-4753-9875-D7AF554A78C5

Q34494226-56693F31-5F86-4D75-8407-7A893FFE4268

Q34494226-95C7A511-B41F-4D8E-9FEE-6EE86E59FF09

Q34494226-CEDB0C37-90DC-47B1-B3C3-C27310F8385A

Q34494226-D67B0D03-926D-4522-A93C-BE686638255B

P2860

Q34494226-15E5D7E0-C21F-4655-8940-C14174A27887

Q34494226-219773E6-0634-443F-9623-0D5A7E9E06A2

Q34494226-257E7685-1DA4-4ED9-8D2F-74146254CD35

Q34494226-2F6C1FE9-1792-4E65-901F-C5AC9158B7A1

Q34494226-34B69EB1-DAB6-4C25-8AC9-79EB91A12985

Q34494226-39C507E8-AB99-454D-BAE9-72B704549A3D

Q34494226-3AAAEC65-163D-41D1-99D7-BABFDFA3D986

Q34494226-46F3FB51-EFAE-4629-9DC6-C32B67C2DBDE

Q34494226-512FB68B-95D0-4840-93BB-354DDF29F179

Q34494226-53100D65-ADA6-498B-B50F-EF4F87C4C2A4

P304

Q34494226-7E3C3B93-D7FB-46DC-A5B5-9A89E150CA6D

P31

Q34494226-28852D67-13A8-433C-B1AA-CA6F1594D452

P356

Q34494226-482912D2-0E6E-427A-ACA2-39E30CDEED51

P407

Q34494226-E676A532-09CB-4B91-B6A3-201E6D81B27D

P433

Q34494226-1A24CC79-187D-4A04-8E08-F042A29CE7A6

P478

Q34494226-9123ACD3-76CB-453D-B4B2-1018611D4FAB

P577

Q34494226-DDC5E8A2-623C-41F0-8435-FA5E3068CA31

P5875

Q34494226-43C97B2C-9298-45C2-ADF8-2F214F171BF6

P698

Q34494226-01521873-F1DC-435F-ACB8-B779D48A1A6C

P356

P1433

Journal of Biological Chemistry

P1476

Structural and molecular interactions of CCR5 inhibitors with CCR5.

@en

P2093

Debananda Das

http://www.w3.org/2001/XMLSchema#string

Eddy Arnold

http://www.w3.org/2001/XMLSchema#string

Gail F Arnold

http://www.w3.org/2001/XMLSchema#string

Hiroaki Mitsuya

http://www.w3.org/2001/XMLSchema#string

Hiromi Ogata-Aoki

http://www.w3.org/2001/XMLSchema#string

Hirotomo Nakata

http://www.w3.org/2001/XMLSchema#string

Jianping Ding

http://www.w3.org/2001/XMLSchema#string

Kenji Maeda

http://www.w3.org/2001/XMLSchema#string

Rachael Norman

http://www.w3.org/2001/XMLSchema#string

Toshikazu Miyakawa

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a major co-receptor for primary isolates of HIV-1

Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

Crystal structure of rhodopsin: A G protein-coupled receptor

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening

P304

12688-12698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M512688200

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

281

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7299730

http://www.w3.org/2001/XMLSchema#string

P698

16476734

http://www.w3.org/2001/XMLSchema#string